Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Nantkwest Inc CS (NK)

Nantkwest Inc CS (NK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 642,336
  • Shares Outstanding, K 98,367
  • Annual Sales, $ 50 K
  • Annual Income, $ -96,230 K
  • 60-Month Beta 2.89
  • Price/Sales 14,236.73
  • Price/Cash Flow N/A
  • Price/Book 4.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.20
  • Number of Estimates 1
  • High Estimate -0.20
  • Low Estimate -0.20
  • Prior Year -0.22
  • Growth Rate Est. (year over year) +9.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.35 +94.44%
on 01/10/20
9.90 -34.21%
on 01/16/20
+2.77 (+74.16%)
since 12/27/19
3-Month
1.05 +520.34%
on 10/31/19
9.90 -34.21%
on 01/16/20
+5.33 (+451.35%)
since 10/25/19
52-Week
0.95 +585.64%
on 06/06/19
9.90 -34.21%
on 01/16/20
+5.35 (+461.52%)
since 01/25/19

Most Recent Stories

More News
Options Traders Expect Huge Moves in NantKwest (NK) Stock

Investors need to pay close attention to NantKwest (NK) stock based on the movements in the options market lately.

NK : 6.68 (+2.30%)
Progress Report on Cancer Breakthroughs 2020 Project Presented by Dr. Soon-Shiong at J.P. Morgan Healthcare Conference

Patrick Soon-Shiong, M.D., Chairman and CEO of NantKwest, Inc. and ImmunityBio, Inc. presented an update of the Cancer Breakthrough 2020 Initiative (the "Initiative") and findings on the preliminary safety...

NK : 6.68 (+2.30%)
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein

NantKwest Inc., (Nasdaq: NK), a clinical-stage natural killer cell-based therapeutics company, today announced results from their Phase 1 trial investigating a novel, first-in-human immunotherapy consisting...

FSNN : 0.0580 (-19.44%)
JPM : 131.33 (-1.37%)
NK : 6.68 (+2.30%)
ImmunityBioto Present at the 38thAnnual J.P. Morgan Healthcare Conference

ImmunityBio, a privately held immunotherapy companyfocused ondevelopinga T-cellmemory cancer vaccine,today announced that Patrick Soon-Shiong, M.D., Chairman and Chief Executive Officer,...

JPM : 131.33 (-1.37%)
NK : 6.68 (+2.30%)
NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy With Durable, Complete Response Data and 78% Disease Control in Refractory Triple Negative Breast Cancer at SABCS

NantKwest Inc. (Nasdaq: NK), a clinical-stage natural killer cell-based therapeutics company, and ImmunityBio, a privately held immunotherapy company, today announced results from their Phase 1b trial...

NK : 6.68 (+2.30%)
SmarTrend Watching for Potential Pullback in Shares of Nantkwest Inc After 2.98% Gain

Nantkwest Inc (NASDAQ:NK) traded in a range yesterday that spanned from a low of $1.69 to a high of $1.74. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $1.69...

NK : 6.68 (+2.30%)
NantKwest Announces Phase 1 Results for First-in-Human PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) in Patients with Locally Advanced or Metastatic Solid Cancers

NantKwest, Inc. (Nasdaq: NK), a clinical-stage natural killer cell-based therapeutics company, today announced promising safety data generated from the first six patients in its QUILT-3.064 trial. The...

NK : 6.68 (+2.30%)
NantKwest Hosting Key Opinion Leader Meeting on Novel Immunotherapeutic Approaches to Address the Unmet Medical Needs of Patients with Merkel Cell Carcinoma, Triple-Negative Breast Cancer and Solid Tumors

NantKwest, Inc. (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious...

NK : 6.68 (+2.30%)
NantKwest Announces Presentation of Positive Phase 2 Clinical Data of Natural Killer Cell Therapy in Metastatic Merkel Cell Carcinoma at SITC 2019

--Data Supportive of Planned Off-the-Shelf Clinical Trial to Confirm Activity and Safety

NK : 6.68 (+2.30%)
Nantkwest Inc Set to Possibly Pullback After Yesterday's Rally of 2.61%

Nantkwest Inc (NASDAQ:NK) traded in a range yesterday that spanned from a low of $1.17 to a high of $1.26. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $1.25...

NK : 6.68 (+2.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade NK with:

Business Summary

NantKwest, Inc. is a clinical-stage immunotherapy company. The Company's product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc....

See More

Key Turning Points

2nd Resistance Point 7.44
1st Resistance Point 6.98
Last Price 6.72
1st Support Level 6.28
2nd Support Level 6.04

See More

52-Week High 9.90
Last Price 6.72
Fibonacci 61.8% 6.48
Fibonacci 50% 5.42
Fibonacci 38.2% 4.37
52-Week Low 0.95

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar